Crémieux
This is actually insane. 97% of people taking the standard of care for metastatic solid tumor got worse by seven years. But with lorlatinib, that number was only 45% in the same time! This is an ENORMOUS jump in the quality of cancer care.
Eric K. Singhi, MD
7yr CROWN update of 1L lorlatinib 55% progression-free at 7 YEARS. Median PFS STILL not reached. In metastatic solid tumors, this is essentially unheard of. Let that sink in. And hopefully, one day, this becomes the standard (or even better) for ALL metastatic cancers.#ASCO26
